Brokers Set Expectations for PSTV Q1 Earnings

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Research analysts at Ascendiant Capital Markets issued their Q1 2027 earnings per share estimates for shares of Plus Therapeutics in a note issued to investors on Wednesday, April 8th. Ascendiant Capital Markets analyst E. Woo expects that the company will earn ($0.74) per share for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share. Ascendiant Capital Markets also issued estimates for Plus Therapeutics’ Q2 2027 earnings at ($0.74) EPS, Q3 2027 earnings at ($0.60) EPS and Q4 2027 earnings at ($0.60) EPS.

Other research analysts also recently issued reports about the company. Wall Street Zen upgraded Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th. Lake Street Capital assumed coverage on Plus Therapeutics in a research report on Tuesday, February 3rd. They set a “buy” rating and a $50.00 price objective on the stock. D. Boral Capital reiterated a “hold” rating on shares of Plus Therapeutics in a research note on Tuesday, March 31st. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price (down from $50.00) on shares of Plus Therapeutics in a report on Friday, January 23rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Plus Therapeutics has an average rating of “Hold” and an average price target of $58.00.

Plus Therapeutics Stock Performance

NASDAQ PSTV opened at $5.43 on Tuesday. The company has a market cap of $37.25 million, a PE ratio of -0.18 and a beta of 1.03. The firm’s 50 day moving average price is $6.15 and its 200-day moving average price is $11.00. Plus Therapeutics has a 52-week low of $2.90 and a 52-week high of $30.50.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Thursday, March 12th. The company reported $6.25 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $6.28. The firm had revenue of $1.37 million during the quarter, compared to the consensus estimate of $1.23 million.

Institutional Trading of Plus Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in Plus Therapeutics during the 2nd quarter valued at approximately $41,000. Susquehanna International Group LLP purchased a new stake in shares of Plus Therapeutics during the third quarter valued at $46,000. Scientech Research LLC acquired a new position in shares of Plus Therapeutics in the 3rd quarter valued at $100,000. XTX Topco Ltd purchased a new position in Plus Therapeutics in the 4th quarter worth $127,000. Finally, State Street Corp raised its stake in Plus Therapeutics by 37.1% in the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after acquiring an additional 127,000 shares during the last quarter. 3.28% of the stock is currently owned by institutional investors and hedge funds.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.